Serologic response to revaccination with two rubella vaccines

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Rubella vaccination is crucial for preventing congenital rubella syndrome.
• Assessing the long-term effectiveness of different rubella vaccine strains and administration routes is important for public health strategies.

Purpose of the Study:

• To compare the immunogenicity of two rubella vaccine strains (HPV-77 DE-5 and RA 27/3) as booster doses.
• To evaluate the impact of subcutaneous versus intranasal administration on antibody responses.
• To determine if a second rubella vaccine dose is necessary for sustained immunity.

Main Methods:

• A study involving 1,060 elementary school children on Maui, Hawaii, three years post-initial rubella vaccination.
• Revaccination with either HPV-77 DE-5 or RA 27/3 rubella vaccine via subcutaneous or intranasal routes.
• Measurement of hemagglutination-inhibiting antibody titers before and after revaccination.

Main Results:

• The RA 27/3 vaccine demonstrated superior booster effectiveness, inducing significant titer rises in 20.1% of recipients.
• Children with pre-existing low antibody titers (≤1:40) showed an 80% response rate to the RA 27/3 vaccine.
• Intranasal administration did not significantly enhance effectiveness over subcutaneous delivery but yielded higher titers in responders.
• Immune responses varied based on the primary vaccine received three years prior.

Conclusions:

• RA 27/3 is a more effective rubella vaccine for boosting antibody titers, particularly in individuals with lower initial immunity.
• Current evidence suggests persistent antibody titers in vaccinated children, making routine second-dose administration unnecessary.
• Further research may be needed to understand long-term immunity differences based on initial vaccine type and response to boosters.